A little more than a year after an unexpected complete response letter, ViiV Healthcare has obtained US Food and Drug Administration approval of Cabenuva, a long-acting, injectable regimen for HIV-positive patients that will enable them to go from daily to monthly dosing. The GlaxoSmithKline plc affiliate announced wholesale acquisition cost (WAC) pricing of $3,960 per month for the two-drug regimen on 22 January, following a first-month price of $5,940 for a higher initiation dose.
ViiV head of research and development Kimberly Smith said the company anticipates that between 10% and 15% of eligible patients will switch to Cabenuva from daily oral therapy